Eli Lilly announced the launch of Humulin R U-500 KwikPen (insulin human injection), a prefilled device containing a highly concentrated formulation of insulin. 

The Food and Drug Administration (FDA) approved Humulin R U-500 KwikPen in January 2016. It is a man-made insulin used to control high blood sugar in adults and children with type 1 and type 2 diabetes who require >200 units of insulin daily. The U-500 formulation is 5 times more concentrated than the standard U-100 insulin, allowing patients with diabetes to inject up to 80% less liquid while receiving the required dose. 

RELATED: Extreme Insulin Requirements in Patient with Rare Genetic Disorder

Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis. 

The Humulin R U-500 is now available as 3mL KwikPens in 2- and 5-count cartons and as 20mL vials.

For more information call (800) 545-5979 or visit Humulin.com.